Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BACE2 is homologous to BACE1, a beta-secretase that is involved in the amyloidogenic pathway of amyloid precursor protein (APP), and maps to the Down syndrome critical region of chromosome 21. Alzheimer disease neuropathology is common in Down syndrome patients at relatively early ages, and it has thus been speculated that BACE2 co-overexpression with APP would promote the early neurodegenerative phenotype. However, the in vivo function of BACE2 has not yet been elucidated. The aim of the present work has been to analyse the impact of in vivo BACE2 overexpression using a transgenic mouse model. Our results suggest that BACE2 is not involved in the amyloidogenic pathway, cognitive dysfunction or cholinergic degeneration. However, TgBACE2 animals showed increased anxiety-like behaviour along with increased numbers of noradrenergic neurones in locus coeruleus, thus suggesting an unexpected role of BACE2 overexpression.

Original publication

DOI

10.1111/j.1601-183X.2009.00538.x

Type

Journal article

Journal

Genes Brain Behav

Publication Date

01/03/2010

Volume

9

Pages

160 - 172

Keywords

Alzheimer Disease, Amyloid Precursor Protein Secretases, Animals, Anxiety, Aspartic Acid Endopeptidases, Darkness, Down Syndrome, Gene Expression Regulation, Enzymologic, Humans, Immunohistochemistry, Locus Coeruleus, Maze Learning, Mice, Mice, Transgenic, Models, Animal, Motor Activity, Neurons, Photosensitivity Disorders, Prosencephalon, RNA, Transcription, Genetic